Admedus Ltd

ABN 35 088 221 078

REGISTERED OFFICE:

26 Harris Road

Malaga WA 6090

PO Box 6879

East Perth WA 6892

T: +61 (0)8 9266 0100

F: +61 (0)8 9266 0199

E: info.au@admedus.com

www.admedus.com

ASX ANNOUNCEMENT Brisbane, 1st May, 2017 ADMEDUS HSV-2 PHASE IIa RESULTS WEBINAR

  • Admedus investor webinar Thursday, 4 May 2017

  • 9am AEST Sydney/Melbourne/Brisbane time; 7am AWST Perth time

Admedus Limited (ASX:AHZ) today announced that it will hold an investor webinar on Thursday, 4 May 2017 to present the results of the HSV-2 Phase IIa program and provide a business overview on the rest of its immunotherapies programs including the HPV treatment program and its work in the area of RNA vaccines.

The webinar details Date: 4 May, 2017 Time: 9am Australian Eastern Standard Time (AEST); 7am Australian Western Standard Time (ASWT) Please register to attend the webinar at:

https://attendee.gotowebinar.com/register/2780413500734718467

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com

For more information, please contact:

Dr Julian Chick

Chief Operating Officer | Admedus Limited T: +61 (0)8 9266 0100

info@admedus.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell T: +44 (0) 20 3727 1000

E: admedus@fticonsulting.com

Signal Leadership Communication Inc. Bob Pickard

T: +1 (647) 822 1000

E: bob.pickard@signaleadership.com

US Investor

Rx Communications Group, LLC Melody A. Carey

T: +1 917 322 2571

E: mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com.

Admedus Ltd. published this content on 01 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 30 April 2017 23:05:16 UTC.

Original documenthttp://clients2.weblink.com.au/clients/admedus/article.asp?asx=AHZ&view=6819370

Public permalinkhttp://www.publicnow.com/view/DB8BFA82FEF174098812247AFD9E75FBEA985316